Testing Responsiveness To Platelet Inhibition On Chronic Antiplatelet Treatment For Acute Coronary Syndromes - TROPICAL-ACS
Contribution To Literature:
The TROPICAL-ACS trial showed that de-escalation of maintenance antiplatelet therapy was noninferior to 1 year of prasugrel.
The goal of the trial was to evaluate de-escalation of maintenance antiplatelet therapy compared with control among patients who received a coronary stent for an acute coronary syndrome.
Patients with acute coronary syndrome who underwent percutaneous coronary intervention (PCI) were randomized to de-escalation of antiplatelet therapy (n = 1,304) vs. prasugrel for 12 months (n = 1,306). In the de-escalation group, participants were treated with prasugrel for 1 week, then clopidogrel for 1 week at which time they underwent platelet function testing. If high platelet reactivity was documented, they were switched back to prasugrel. Otherwise, they remained on clopidogrel for 1 year.
- ST-segment elevation MI (STEMI) or NSTEMI
- Underwent PCI
- Planned use of prasugrel for 12 months
- Total number of enrollees: 2,610
- Duration of follow-up: 12 months
- Mean patient age: 59 years
- Percentage female: 78%
- Percentage with diabetes: 22%
Other salient features/characteristics:
- Presentation: STEMI in 55%, NSTEMI in 45%
The primary outcome, incidence of cardiovascular death, MI, stroke, or bleeding (Bleeding Academic Research Consortium [BARC] ≥2), occurred in 7% of the de-escalation group vs. 9% of the control group (p for noninferiority = 0.0004).
- All-cause mortality: 1% vs. 1% (p = 0.85), respectively, for de-escalation vs. control
- MI: 2% vs. 2% (p = 0.59), respectively, for de-escalation vs. control
- BARC type 3 or 5 bleeding: 2% vs. 1% (p = 0.63), respectively, for de-escalation vs. control
Among patients with acute coronary syndrome (STEMI or NSTEMI), de-escalation of maintenance antiplatelet therapy was noninferior to 12 months of prasugrel. De-escalation of antiplatelet therapy was guided by platelet function testing. This strategy was associated with noninferiority regarding the primary outcome of cardiovascular death, MI, stroke, or bleeding BARC ≥2. Especially if affordability of medications is an issue, this approach could be an alternative.
Sibbing D, Aradi D, Jacobshagen C, et al., on behalf of the TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndromes undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicenter trial. Lancet 2017;390:1747-57.
Editorial Comment: Angiolillo DJ. Dual antiplatelet therapy guided by platelet function testing. Lancet 2017;390:1718-20.
Presented by Dr. Dirk Sibbing at the European Society of Cardiology Congress, Barcelona, Spain, August 27, 2017.
< Back to Listings